The premium market intelligence study by BIS Research titled Narcolepsy Therapeutics Market - A Global and Country-Level Analysis projects the market to reach $4.91 billion in terms of revenue by 2032, at a CAGR of 15.93%.

In this comprehensive study of the global narcolepsy therapeutics market, BIS Research extensively covers the following:

  • Market numbers on micro-segments that are influencing the market 
  • Regulatory framework analysis and reimbursement scenario in developed and developing regions
  • Current and future therapies' potential
  • Detailed country-level market share analysis, including the scrutiny of seven major markets 
  • Study of data of more than nine companies actively involved in the development of advanced narcolepsy treatments

Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of all prominent products. 

To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include indications, therapeutics, and seven major markets, including the U.S., the U.K., Germany, France, Spain, Italy, and Japan.

The detailed study is a compilation of 25 market data tables and 112 figures spread through 151 pages and an in-depth TOC on "Global Narcolepsy Therapeutics Market  – Analysis and Forecast, 2022-2032"

Demand – Drivers and Limitations

Following are the demand drivers for the global narcolepsy therapeutics market:

  • Large population of undiagnosed and untreated narcolepsy population
  • Increasing research funding for neuroscience
  • Approval of advanced therapies with a novel mechanism of action (MoA)
  • Existing unmet needs of patients and healthcare professionals (HCPs)

The market is expected to face some limitations due to the following challenges:

  • Delayed diagnosis
  • Lack of awareness

Reasons to Buy This Report

This exclusive report on the global narcolepsy therapeutics market will help in the following ways:

  •  Aid in product development
  • Help in targeting a segment for launching a new product
  • Offer go-to-market access strategies
  • Support in diversifying the product portfolio basis risk
  • Help in analyzing therapy substitutes and compare specifications
  • Help gain holistic views pertaining to the key countries and understand the market potential of the countries
  • Support in analyzing the competitive landscape to gain an understanding of the business strategies incorporated by the companies

Analyst's Take on the Market:

According to Abdul Wahid, Principal Consultant – BIS Research, "The U.S. is the market leader in the global narcolepsy therapeutics market. In 2021, the U.S. accounted for a 93.48% share in the global narcolepsy therapeutics market. The country is anticipated to retain its position and grow significantly during the forecast period 2022-2032."

View the report on the Global Narcolepsy Therapeutics Market

Key Companies Operating in the Market and Competitive Landscape

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent players in this market are:

•   Jazz Pharmaceuticals PLC
•   Harmony Bioscience, LLC
•   Axsome Therapeutics, Inc.
•   Avadel Pharmaceuticals PLC
•   Takeda Pharmaceutical Co Ltd
•   Sumitomo Pharma Co Ltd
•   Suven Life Sciences Limited
•   NLS Pharmaceutics AG
•   Balance Therapeutics

Request a Sample of this Report

Key Questions Answered in the Report:

  • What are the major market drivers, challenges, and opportunities in the global narcolepsy therapeutics market?
  • What are the key development strategies implemented by the major players to sustain in the competitive market?
  • Which is the dominant therapeutic type developed by the leading and emerging players for narcolepsy?
  • What are the key class of drugs that have been considered by leading players in the global narcolepsy therapeutics market?
  • What are the most promising emerging and investigational therapies in narcolepsy?
  • Which companies are anticipated to be highly disruptive in the future, and why?
  • What are the reimbursement scenarios and the regulations for narcolepsy in the seven aforementioned major markets?
  • What are the treatment guidelines for narcolepsy in seven major markets?